Document is current

Article History

Received: 14 August 2023

Accepted: 11 October 2023

First Online: 13 October 2023

Declarations

:

: Data abstraction and analysis was undertaken as a Quality Improvement initiative within the University of Alabama at Birmingham Pediatric Rheumatology Division, with the goal to improve the appointment referral process and decrease appointment wait times. As such, this project did not meet the formal definition of research per the US Department of Health and Human Services and was not formally supervised by the Institutional Review Board per policy.

: Manuscript does not contain any specific individual’s data. Not applicable.

: None of the above authors report any relationships, conflicts of interest, or commercial interests specifically related to the submitted manuscript.RQC declares consulting fees for Sobi regarding the use of anakinra in clinical trials to treat macrophage activation syndrome; textbook royalties from Springer; speaker fees from Lilly, Sobi, MedStudy, and Arthros Rheum; and consulting or advisory fees from Sironax and CareerPhysician. RQC also serves on adjudication committees and has received personal fees to establish episodes of macrophage activation syndrome among patients enrolled in clinical trials (funded by Pfizer and AbbVie) for therapeutics used to treat juvenile idiopathic arthritis. RQC holds a patent on detecting rare long non-coding RNA mutations in people with COVID-19 unrelated to the content of this report.EAS and MLM are both supported by the Rheumatology Research Foundation Investigator Award.DDR, JMB, ECR, VLG, LM, AR, CS, BW, PW, and MLS declare no conflicts of interest.